|
業務類別
|
Biotechnology |
|
業務概覽
|
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approachesto clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novelpayloads. |
| 公司地址
| 175 Innovation Boulevard, Wilmington, DE, USA, 19805 |
| 電話號碼
| +1 302 467-1280 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.preludetx.com |
| 員工數量
| 79 |
| Dr. Krishna Vaddi, PhD |
Director and Chief Executive Officer |
美元 594.17K |
10/03/2026 |
| Ms. Peggy A. Scherle, PhD |
Chief Scientific Officer |
-- |
29/04/2025 |
| Mr. Andrew P. Combs, PhD |
Chief Chemistry Officer |
-- |
29/04/2025 |
| Mr. Bryant D. Lim |
Chief Financial Officer, Chief Legal Officer, Principal Accounting Officer and Corporate Secretary |
美元 444.17K |
10/03/2026 |
| Dr. Charles Morris, M.R.C.P. |
Chief Medical Officer |
-- |
15/04/2026 |
|
|
| Ms. Katina Dorton, J.D.,M.B.A. |
Director |
10/03/2026 |
| Mr. Martin Babler |
Independent Director |
10/03/2026 |
| Dr. Krishna Vaddi, PhD |
Director and Chief Executive Officer |
10/03/2026 |
| Dr. Victor Sandor, C.M.,PhD |
Independent Director |
10/03/2026 |
| Dr. David P. Bonita, M.D. |
Independent Director |
10/03/2026 |
| Dr. Paul A. Friedman,M.D. |
Chairman of the Board |
10/03/2026 |
| Dr. Paul C. Scherer, M.D.,Pd.D |
Director |
10/03/2026 |
|
|
|
|
